

# COMBINATION OF TWO RAPID OPHTHALMIC TEST KITS IMPROVES ETIOLOGIC DIAGNOSIS IN CASES OF SEVERE BINOCULAR CONJUNCTIVITIS



Medical history assesement  
Slit examination





Table 2. Results of Capilia Adeno Eye® and Allerwatch®.

|                 | Capilia Adeno Eye® | Allerwatch®             | Capilia Adeno Eye® and/or Allerwatch® |
|-----------------|--------------------|-------------------------|---------------------------------------|
| Positive        | 12                 | Grade2, 38<br>Grade1, 6 | 55                                    |
| Negative        | 48                 | Grade0, 16              | 5                                     |
| Positivity Rate | 12/60 (20%)        | 44/60 (73.3%)           | 55/60 (91.7%)                         |

# LES CHAMBRES D'EXPOSITION ENVIRONNEMENTALE SE RAPPROCHENT DE L'EXPOSITION NATURELLE POUR L'ÉVALUATION DES CONJONCTIVITES ALLERGIQUES



- Etudes longues
- Variabilité de l'exposition allergénique
- Variabilité des conditions météorologiques



- Gold standard (FDA)
- Réponse oculaire à l'allergène donné par inoculation directe



- Exposition contrôlée à grande échelle
- Sensibilité, spécificité, reproductibilité, sécurité
- Etude hors saison pollinique
- Pas d'interférence météo
- Toutes les muqueuses
- Sujets volontaires

Bonne  
corrélation score  
oculaire / score  
de rhinite

Bonne  
corrélation CEE  
et exposition  
naturelle

TABLE I. Symptom correlation in the natural season versus the PCC


| Symptom comparison       | Natural season<br>(n = 31) |         | PCC (n = 26) |         |
|--------------------------|----------------------------|---------|--------------|---------|
|                          | R                          | P value | R            | P value |
| TOSS components          |                            |         |              |         |
| Eye itch vs tears        | 0.83                       | <.0001  | 0.68         | <.0001  |
| Eye itch vs redness      | 0.81                       | <.0001  | 0.62         | .0005   |
| Tears vs redness         | 0.76                       | <.0001  | 0.55         | .003    |
| TNSS components          |                            |         |              |         |
| Congestion vs nasal itch | 0.79                       | <.0001  | 0.71         | <.0001  |
| Congestion vs sneezing   | 0.52                       | .0057   | 0.28         | .168    |
| Congestion vs runny nose | 0.88                       | <.0001  | 0.85         | <.0001  |
| Nasal itch vs sneezing   | 0.53                       | .0047   | 0.17         | .41     |
| Nasal itch vs runny nose | 0.79                       | <.0001  | 0.61         | .0007   |
| Sneezing vs runny nose   | 0.54                       | .0038   | 0.39         | .048    |
| TSS components           |                            |         |              |         |
| TOSS vs TNSS             | 0.86                       | <.0001  | 0.52         | .0057   |

Tableau 2 Récapitulatif des différentes expositions allergéniques responsables de symptômes bronchiques et oculaires lors d'une exposition naturelle, d'un test de provocation individuel et dans la CEE [7].

|                      | Exposition naturelle             | Test de provocation individuel   | CEE                              |
|----------------------|----------------------------------|----------------------------------|----------------------------------|
| Poussière d'acariens | 12                               | 23                               | 12                               |
| Der p1 (ng)          |                                  |                                  |                                  |
| Chat                 | 4,2                              | 13                               | 19                               |
| Fel d1 (ng)          |                                  |                                  |                                  |
| Pollen de bouleau    | 8000 gr de pollen/m <sup>3</sup> | 98000gr de pollen/m <sup>3</sup> | 6000 gr de pollen/m <sup>3</sup> |
| Bet v1 (ng)          | 80 ng/m <sup>3</sup>             | 980 ng/m <sup>3</sup>            | 60 ng/m <sup>3</sup>             |
|                      | 2,1 pg/2 yeux                    | 980 000 pg/œil                   | 1,6 pg/2 yeux                    |

# LES COLLYRES DE CYCLOSPORINE A SOUS FORME D'ÉMULSION CATIONIQUE SONT D'UTILISATION SÛRE DANS LE TRAITEMENT DES KERATOCONJONCTIVITES VERNALES DE L'ENFANT

## The VEKTIS Study





Ex : IKERVIS 1mg/ml collyre de cyclosporine A

**TABLE 2.** Summary of Treatment-Emergent Adverse Events (TEAEs) During 8-Month Follow-up Period and Entire 12-Month Study

| Parameter                                 | Follow-Up Period (Months 4-12) |                               | Entire Study (Months 0-12)    |                               |
|-------------------------------------------|--------------------------------|-------------------------------|-------------------------------|-------------------------------|
|                                           | CsA CE QID, n (%)<br>(n = 72)  | CsA CE BID, n (%)<br>(n = 70) | CsA CE QID, n (%)<br>(n = 72) | CsA CE BID, n (%)<br>(n = 70) |
| Patients with ≥1 TEAEs                    | 27 (37.5)                      | 23 (32.9)                     | 42 (58.3)                     | 35 (50.0)                     |
| Patients with treatment-related TEAEs     | 4 (5.6)                        | 6 (8.6)                       | 15 (20.8)                     | 11 (15.7)                     |
| Patients with serious TEAEs               | 1 (1.4)                        | 0 (0)                         | 3 (4.2)                       | 1 (1.4)                       |
| Discontinuations due to TEAEs             | 1 (1.4)                        | 0 (0)                         | 1 (1.4)                       | 0 (0)                         |
| Discontinuations due to treatment-related | 1 (1.4)                        | 0 (0)                         | 1 (1.4)                       | 0 (0)                         |
| <b>TEAEs</b>                              |                                |                               |                               |                               |
| <b>Most common TEAEs</b>                  |                                |                               |                               |                               |
| <b>Eye disorders<sup>a</sup></b>          |                                |                               |                               |                               |
| Ocular hyperemia                          | 4 (5.6)                        | 0 (0)                         | 4 (5.6)                       | 1 (1.4)                       |
| Eye pruritus                              | 3 (4.2)                        | 1 (1.4)                       | 3 (4.2)                       | 1 (1.4)                       |
| Corneal leukoma                           | 1 (1.4)                        | 0 (0)                         | 2 (2.8)                       | 1 (1.4)                       |
| Ulcerative keratitis                      | 0 (0)                          | 1 (1.4)                       | 2 (2.8)                       | 1 (1.4)                       |
| Eye irritation                            | 0 (0)                          | 1 (1.4)                       | 0 (0)                         | 2 (2.9)                       |
| Ocular discomfort                         | 2 (2.8)                        | 0 (0)                         | 2 (2.8)                       | 0 (0)                         |
| <b>Other TEAEs<sup>b</sup></b>            |                                |                               |                               |                               |
| Instillation site pain                    | 2 (2.8)                        | 2 (2.9)                       | 10 (13.9)                     | 5 (7.1)                       |
| Instillation site pruritus                | 1 (1.4)                        | 2 (2.9)                       | 5 (6.9)                       | 4 (5.7)                       |
| Headache                                  | 2 (2.8)                        | 1 (1.4)                       | 5 (6.9)                       | 1 (1.4)                       |
| Instillation site erythema                | 0 (0)                          | 1 (1.4)                       | 3 (4.2)                       | 2 (2.9)                       |
| Nasopharyngitis                           | 3 (4.2)                        | 2 (2.9)                       | 3 (4.2)                       | 6 (8.6)                       |
| Influenza                                 | 4 (5.6)                        | 0 (0)                         | 4 (5.6)                       | 0 (0)                         |
| Cough                                     | 2 (2.8)                        | 0 (0)                         | 4 (5.6)                       | 0 (0)                         |
| Pyrexia                                   | 1 (1.4)                        | 1 (1.4)                       | 1 (1.4)                       | 3 (4.3)                       |


# DES LENTILLES DE CONTACT À BASE DE NANOPARTICULES POUR LA PRISE EN CHARGE DES CONJONCTIVITES ALLERGIQUES ·

## EXEMPLE DU KETOTIFENE = ANTIHISTAMINIQUE H1



**Fig. 2.** Ketotifen release rate (ng/h) from the contact lenses (Mean  $\pm$  standard deviation,  $n = 3$ ).

IN VITRO





**Fig. 3.** *In vivo* release of ketotifen in the tear fluid from the contact lenses (Mean  $\pm$  standard deviation,  $n = 6$ ).

IN VIVO



# COVID-19 : REMISE EN QUESTION DANS LA PRISE EN CHARGE DES ALLERGIES OCULAIRES ?



## CONJONCTIVITE SAISONNIERE

| Topical antiallergic drops |          |                 |                    |          |            |
|----------------------------|----------|-----------------|--------------------|----------|------------|
| SARS-CoV-2 infection       | Agree    | Partially agree | Partially disagree | Disagree | No opinion |
| Not at risk, n (%)         | 28 (93%) | 1 (3%)          | 0                  | 0        | 0          |
| At risk, n (%)             | 29 (97%) | 0               | 0                  | 0        | 0          |
| Current infection, n (%)   | 29 (97%) | 0               | 0                  | 0        | 0          |
| Previous infection, n (%)  | 28 (93%) | 1 (3%)          | 0                  | 0        | 0          |

| Low-dose topical corticosteroids in case of no response |          |          |         |          |   |
|---------------------------------------------------------|----------|----------|---------|----------|---|
| Not at risk, n (%)                                      | 14 (47%) | 10 (33%) | 1 (3%)  | 3 (10%)  | 0 |
| At risk, n (%)                                          | 10 (33%) | 6 (20%)  | 1 (3%)  | 12 (40%) | 0 |
| Current infection, n (%)                                | 9 (30%)  | 4 (13%)  | 3 (10%) | 13 (43%) | 0 |
| Previous infection, n (%)                               | 13 (43%) | 10 (33%) | 1 (3%)  | 6 (20%)  | 0 |

| Only oral antihistamines  |         |         |         |          |        |
|---------------------------|---------|---------|---------|----------|--------|
| Not at risk, n (%)        | 10 (3%) | 2 (7%)  | 4 (13%) | 11 (37%) | 0      |
| At risk, n (%)            | 8 (27%) | 8 (27%) | 3 (10%) | 9 (30%)  | 1 (3%) |
| Current infection, n (%)  | 6 (20%) | 4 (13%) | 6 (20%) | 11 (37%) | 0      |
| Previous infection, n (%) | 8 (27%) | 1 (3%)  | 7 (23%) | 11 (37%) | 0      |

## KERATOCONJONCTIVITE VERNALE ET ATOPIQUE

| Topical antiallergic drops |          |                 |                    |          |            |
|----------------------------|----------|-----------------|--------------------|----------|------------|
| SARS-CoV-2 infection       | Agree    | Partially agree | Partially disagree | Disagree | No opinion |
| Not at risk, n (%)         | 26 (87%) | 2 (7%)          | 0                  | 0        | 0          |
| At risk, n (%)             | 26 (87%) | 0               | 1 (3%)             | 0        | 1 (3%)     |
| Current infection, n (%)   | 26 (87%) | 0               | 1 (3%)             | 0        | 1 (3%)     |
| Previous infection, n (%)  | 25 (83%) | 1 (3%)          | 1 (3%)             | 0        | 1 (3%)     |

| Topical corticosteroids as needed as pulse therapy |          |          |         |         |        |
|----------------------------------------------------|----------|----------|---------|---------|--------|
| Not at risk, n (%)                                 | 26 (87%) | 2 (7%)   | 0       | 0       | 1 (3%) |
| At risk, n (%)                                     | 15 (50%) | 9 (30%)  | 1 (3%)  | 2 (7%)  | 1 (3%) |
| Current infection, n (%)                           | 12 (40%) | 7 (17%)  | 6 (20%) | 4 (13%) | 2 (7%) |
| Previous infection, n (%)                          | 16 (53%) | 10 (33%) | 1 (3%)  | 1 (3%)  | 1 (3%) |

| Topical corticosteroids as needed at low dose but long term |         |         |         |          |        |
|-------------------------------------------------------------|---------|---------|---------|----------|--------|
| Not at risk, n (%)                                          | 6 (20%) | 2 (7%)  | 6 (20%) | 10 (33%) | 1 (3%) |
| At risk, n (%)                                              | 2 (7%)  | 5 (17%) | 6 (20%) | 13 (43%) | 1 (3%) |
| Current infection, n (%)                                    | 2 (7%)  | 2 (7%)  | 7 (23%) | 14 (47%) | 2 (7%) |
| Previous infection, n (%)                                   | 4 (13%) | 2 (7%)  | 9 (30%) | 10 (33%) | 1 (3%) |

| Topical calcineurin inhibitors |          |          |         |         |         |
|--------------------------------|----------|----------|---------|---------|---------|
| Not at risk, n (%)             | 20 (67%) | 7 (23%)  | 1 (3%)  | 0       | 1 (3%)  |
| At risk, n (%)                 | 10 (33%) | 10 (33%) | 4 (13%) | 2 (7%)  | 3 (10%) |
| Current infection, n (%)       | 8 (27%)  | 7 (23%)  | 5 (17%) | 7 (23%) | 2 (7%)  |
| Previous infection, n (%)      | 14 (47%) | 9 (30%)  | 1 (3%)  | 2 (7%)  | 3 (10%) |